# Evaluation of the Safety and the Efficacy of Carfilzomib Combined With Cyclophosphamide and Dexamethasone (CCyd) or Lenalidomide and Dex (CRd) Followed by ASCT or 12 Cycles of Carf Combined With Dex and Len for Patients Eligible for ASCT With Newly Diagnosed Multiple Myeloma.

> **NCT02203643** · PHASE2 · COMPLETED · sponsor: **Mario Boccadoro** · enrollment: 477 (actual)

## Conditions studied

- MULTIPLE MYELOMA (MM)

## Interventions

- **DRUG:** Carfilzomib
- **DRUG:** Cyclophosphamide
- **DRUG:** Lenalidomide
- **DRUG:** Dexamethasone

## Key facts

- **NCT ID:** NCT02203643
- **Lead sponsor:** Mario Boccadoro
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-02
- **Primary completion:** 2016-10
- **Final completion:** 2026-03-30
- **Target enrollment:** 477 (ACTUAL)
- **Last updated:** 2026-04-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02203643

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02203643, "Evaluation of the Safety and the Efficacy of Carfilzomib Combined With Cyclophosphamide and Dexamethasone (CCyd) or Lenalidomide and Dex (CRd) Followed by ASCT or 12 Cycles of Carf Combined With Dex and Len for Patients Eligible for ASCT With Newly Diagnosed Multiple Myeloma.". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02203643. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*